These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 34238584)

  • 21. Interferon-α2 Auto-antibodies in Convalescent Plasma Therapy for COVID-19.
    Raadsen MP; Gharbharan A; Jordans CCE; Mykytyn AZ; Lamers MM; van den Doel PB; Endeman H; van den Akker JPC; GeurtsvanKessel CH; Koopmans MPG; Rokx C; Goeijenbier M; van Gorp ECM; Rijnders BJA; Haagmans BL
    J Clin Immunol; 2022 Feb; 42(2):232-239. PubMed ID: 34767118
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Case Report: Effects of Anti-SARS-CoV-2 Convalescent Antibodies Obtained With Double Filtration Plasmapheresis.
    Curtò D; Tomatis F; Gastoldi S; Galbusera M; Noris M; Raimondi F; Lorini FL; Falanga A; Marchetti M; Remuzzi G; Ruggenenti P
    Front Immunol; 2021; 12():711915. PubMed ID: 34276706
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Severe Acute Respiratory Syndrome Coronavirus-2 Pneumonia in a Newborn Treated With Remdesivir and Coronavirus Disease 2019 Convalescent Plasma.
    Hopwood AJ; Jordan-Villegas A; Gutierrez LD; Cowart MC; Vega-Montalvo W; Cheung WL; McMahan MJ; Gomez MR; Laham FR
    J Pediatric Infect Dis Soc; 2021 May; 10(5):691-694. PubMed ID: 33306130
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Structural Basis of a Human Neutralizing Antibody Specific to the SARS-CoV-2 Spike Protein Receptor-Binding Domain.
    Yang M; Li J; Huang Z; Li H; Wang Y; Wang X; Kang S; Huang X; Wu C; Liu T; Jia Z; Liang J; Yuan X; He S; Chen X; Zhou Z; Chen Q; Liu S; Li J; Zheng H; Liu X; Li K; Yao X; Lang B; Liu L; Liao HX; Chen S
    Microbiol Spectr; 2021 Oct; 9(2):e0135221. PubMed ID: 34643438
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Severe acute respiratory syndrome-coronavirus-2: Current advances in therapeutic targets and drug development.
    Suganya S; Divya S; Parani M
    Rev Med Virol; 2021 May; 31(3):e2174. PubMed ID: 32965078
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Treatment of COVID-19 with convalescent plasma: lessons from past coronavirus outbreaks.
    Wooding DJ; Bach H
    Clin Microbiol Infect; 2020 Oct; 26(10):1436-1446. PubMed ID: 32791241
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Adjunct Immunotherapies for the Management of Severely Ill COVID-19 Patients.
    Bonam SR; Kaveri SV; Sakuntabhai A; Gilardin L; Bayry J
    Cell Rep Med; 2020 May; 1(2):100016. PubMed ID: 32562483
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Clinical Management of Patients With B-Cell Depletion Agents to Treat or Prevent Prolonged and Severe SARS-COV-2 Infection: Defining a Treatment Pathway.
    D'Abramo A; Vita S; Maffongelli G; Beccacece A; Agrati C; Cimini E; Colavita F; Giancola ML; Cavasio A; Nicastri E;
    Front Immunol; 2022; 13():911339. PubMed ID: 35711444
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Therapeutic Measures for the Novel Coronavirus: A Review of Current Status and Future Perspective.
    Shahverdi M; Darvish M
    Curr Mol Med; 2021; 21(7):562-572. PubMed ID: 33272178
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Innate and adaptive immune responses against coronavirus.
    Hosseini A; Hashemi V; Shomali N; Asghari F; Gharibi T; Akbari M; Gholizadeh S; Jafari A
    Biomed Pharmacother; 2020 Dec; 132():110859. PubMed ID: 33120236
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Remdesivir in Coronavirus Disease 2019 patients treated with anti-CD20 monoclonal antibodies: a case series.
    Rüfenacht S; Gantenbein P; Boggian K; Flury D; Kern L; Dollenmaier G; Kohler P; Albrich WC
    Infection; 2022 Jun; 50(3):783-790. PubMed ID: 35426564
    [TBL] [Abstract][Full Text] [Related]  

  • 32. An update of anti-viral treatment of COVID-19.
    Şimşek-Yavuz S; Komsuoğlu Çelikyurt FI
    Turk J Med Sci; 2021 Dec; 51(SI-1):3372-3390. PubMed ID: 34391321
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A case of severe course of COVID-19 treated with experimental therapy.
    Zlámal M; Štěchovská K; Holub M
    Cas Lek Cesk; 2020; 159(5):181-184. PubMed ID: 33297704
    [TBL] [Abstract][Full Text] [Related]  

  • 34. SARS-CoV-2 T Cell Response in Severe and Fatal COVID-19 in Primary Antibody Deficiency Patients Without Specific Humoral Immunity.
    Steiner S; Schwarz T; Corman VM; Gebert L; Kleinschmidt MC; Wald A; Gläser S; Kruse JM; Zickler D; Peric A; Meisel C; Meyer T; Staudacher OL; Wittke K; Kedor C; Bauer S; Besher NA; Kalus U; Pruß A; Drosten C; Volk HD; Scheibenbogen C; Hanitsch LG
    Front Immunol; 2022; 13():840126. PubMed ID: 35359967
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Anti-SARS-CoV-2 hyperimmune plasma workflow.
    Annamaria P; Eugenia Q; Paolo S
    Transfus Apher Sci; 2020 Oct; 59(5):102850. PubMed ID: 32540345
    [TBL] [Abstract][Full Text] [Related]  

  • 36. COVID-19 Therapeutics for Solid Organ Transplant Recipients; 6 Months Into the Pandemic: Where Are We Now?
    Avery RK
    Transplantation; 2021 Jan; 105(1):56-60. PubMed ID: 33141805
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Antiviral Activity of Type I, II, and III Interferons Counterbalances ACE2 Inducibility and Restricts SARS-CoV-2.
    Busnadiego I; Fernbach S; Pohl MO; Karakus U; Huber M; Trkola A; Stertz S; Hale BG
    mBio; 2020 Sep; 11(5):. PubMed ID: 32913009
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Therapeutic monoclonal antibodies for COVID-19 management: an update.
    Chavda VP; Prajapati R; Lathigara D; Nagar B; Kukadiya J; Redwan EM; Uversky VN; Kher MN; Patel R
    Expert Opin Biol Ther; 2022 Jun; 22(6):763-780. PubMed ID: 35604379
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Novel Coronavirus: A Review from Origin to Current Status of Therapeutic Strategies.
    Hassan M; Zalkifal M; Wahab A; Afzal S; Rafique S; Shahid M; Khan MA; Ahmed N; Idrees M; Shahid AA
    Crit Rev Eukaryot Gene Expr; 2021; 31(3):21-34. PubMed ID: 34369712
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Possible treatment and strategies for COVID-19: review and assessment.
    Trivedi N; Verma A; Kumar D
    Eur Rev Med Pharmacol Sci; 2020 Dec; 24(23):12593-12608. PubMed ID: 33336780
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.